Previous Close | 10.91 |
1-Year Change | -15.43% |
6-Months Change | -9.08% |
3-Months Change | 11.33% |
Moving Avg (50d) | 10.987 |
Moving Avg (200d) | 11.433 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.17B |
Beta (3-Years) | 1.1 |
Revenue Growth (ttm) | 15.18% |
Net Profit Margin (ttm) | -46.62% |
Return On Assets (ttm) | -22.72% |
EPS (ttm) | -0.59 |
PE Ratio (ttm) | -18.49 |
Dividend Yield | % |
Asset Description: | Amicus Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
11.128 | 11.455 | 11.674 | 12.001 | 12.546 | 13.092 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.